Movement Alert｜AKESO Falls 3.04% in Regular Trading, Profit-Taking Follows WCLC Data Catalyst Digestion

Market Focus09-16

On September 16, AKESO fell 3.04% in regular trading, trading at HK$92.1/share, with turnover of HK$87.24 million. The decline reflects profit-taking after the company's positive HARMONi-2 overall survival data, presented at the World Conference on Lung Cancer, had already driven the stock up over 5% on September 14.

The WCLC presentation revealed that ivonescimab achieved a median OS of 30.8 months versus 22.6 months for pembrolizumab, with a hazard ratio of 0.73 and a median follow-up of 36 months. While multiple investment banks — including Jefferies (target HK$226), Citi (target HK$171), and JPMorgan — maintained bullish ratings following the data, short selling accounted for 33.18% of turnover on September 15, signaling the positive catalyst had been fully absorbed. Additionally, the company's interim results disclosed in late August showed revenue of RMB 1.806 billion, up 28%, with gross profit of RMB 1.34 billion — both falling short of certain institutional expectations — adding further pressure on near-term sentiment.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1153063904?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-16 09:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1153063904","market":"hk","top_or_hot":-1,"title":"Movement Alert｜AKESO Falls 3.04% in Regular Trading, Profit-Taking Follows WCLC Data Catalyst Digestion","media":"Market Focus","content":"<p><p>On September 16, AKESO fell 3.04% in regular trading, trading at HK$92.1/share, with turnover of HK$87.24 million. The decline reflects profit-taking after the company's positive HARMONi-2 overall survival data, presented at the World Conference on Lung Cancer, had already driven the stock up over 5% on September 14.</p><p>The WCLC presentation revealed that ivonescimab achieved a median OS of 30.8 months versus 22.6 months for pembrolizumab, with a hazard ratio of 0.73 and a median follow-up of 36 months. While multiple investment banks — including Jefferies (target HK$226), Citi (target HK$171), and JPMorgan — maintained bullish ratings following the data, short selling accounted for 33.18% of turnover on September 15, signaling the positive catalyst had been fully absorbed. Additionally, the company's interim results disclosed in late August showed revenue of RMB 1.806 billion, up 28%, with gross profit of RMB 1.34 billion — both falling short of certain institutional expectations — adding further pressure on near-term sentiment.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜AKESO Falls 3.04% in Regular Trading, Profit-Taking Follows WCLC Data Catalyst Digestion</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜AKESO Falls 3.04% in Regular Trading, Profit-Taking Follows WCLC Data Catalyst Digestion\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-09-16 09:34</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On September 16, AKESO fell 3.04% in regular trading, trading at HK$92.1/share, with turnover of HK$87.24 million. The decline reflects profit-taking after the company's positive HARMONi-2 overall survival data, presented at the World Conference on Lung Cancer, had already driven the stock up over 5% on September 14.</p><p>The WCLC presentation revealed that ivonescimab achieved a median OS of 30.8 months versus 22.6 months for pembrolizumab, with a hazard ratio of 0.73 and a median follow-up of 36 months. While multiple investment banks — including Jefferies (target HK$226), Citi (target HK$171), and JPMorgan — maintained bullish ratings following the data, short selling accounted for 33.18% of turnover on September 15, signaling the positive catalyst had been fully absorbed. Additionally, the company's interim results disclosed in late August showed revenue of RMB 1.806 billion, up 28%, with gross profit of RMB 1.34 billion — both falling short of certain institutional expectations — adding further pressure on near-term sentiment.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09926","symbol_name":"康方生物","start_time":0,"source_url":"","article_id":"1153063904","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1153063904","pubTimestamp":1789522469,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On September 16, AKESO fell 3.04% in regular trading, trading at HK$92.1/share, with turnover of HK$87.24 million. The decline reflects profit-taking after the company's positive HARMONi-2 overall...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"09926":"康方生物"},"translate_title":"走势警报|AKESO 常规交易下跌 3.04%，WCLC 数据催化剂消化后获利了结","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09926":1},"content_text":"On September 16, AKESO fell 3.04% in regular trading, trading at HK$92.1/share, with turnover of HK$87.24 million. The decline reflects profit-taking after the company's positive HARMONi-2 overall survival data, presented at the World Conference on Lung Cancer, had already driven the stock up over 5% on September 14.The WCLC presentation revealed that ivonescimab achieved a median OS of 30.8 months versus 22.6 months for pembrolizumab, with a hazard ratio of 0.73 and a median follow-up of 36 months. While multiple investment banks — including Jefferies (target HK$226), Citi (target HK$171), and JPMorgan — maintained bullish ratings following the data, short selling accounted for 33.18% of turnover on September 15, signaling the positive catalyst had been fully absorbed. Additionally, the company's interim results disclosed in late August showed revenue of RMB 1.806 billion, up 28%, with gross profit of RMB 1.34 billion — both falling short of certain institutional expectations — adding further pressure on near-term sentiment.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.50.0","shortVersion":"4.50.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1153063904","isCrawlerRequest":true}